Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Pathogenetic aspects of vasculotoxicity of antitumor chemotherapy

Authors: Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Misrikhanova F.E., Akildzhonov F.R.

Company:
Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

DOI: https://doi.org/10.24022/1814-6910-2026-23-1-5-12

UDC: 615.277.3

Link: Clinical Physiology of Blood Circulaiton. 2026; 23 (1): 5-12

Quote as: Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Misrikhanova F.E., Akildzhonov F.R. Pathogenetic aspects of vasculotoxicity of antitumor chemotherapy. Clinical Physiology of Circulation. 2026; 23 (1): 5–12 (in Russ.). DOI: 10.24022/1814-6910-2026-23-1-5-12

Received / Accepted:  23.12.2025 / 22.01.2026

Full text:
Subscribe 🔒

Abstract

The decline in cancer patient survival despite effective antitumor therapy is accompanied by an increased incidence of cardiovascular complications, particularly vasculotoxicity. This term refers to endothelial damage and hemostasis disorders caused by chemotherapy, targeted therapy, and immunotherapy. It is the second most common group of cardio-oncological complications, characterized by thromboembolism, arterial and pulmonary hypertension, vasospasm, and accelerated atherosclerosis. This review systematizes current data (2020–2025) on the pathophysiological mechanisms and clinical forms of vasculotoxicity. The goal of this work is to provide a basis for developing algorithms for the prevention and monitoring of these complications, a key objective of modern cardio-oncology for maintaining quality of life and improving the long-term prognosis of patients.

 If you found mistakes, select text and press Alt+A